RecruitingEarly Phase 1NCT04741997

Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma

Studying Germ cell tumor

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Principal Investigator
Zeynep Eroglu, MD
Moffitt Cancer Center
Intervention
Encorafenib Pill(drug)
Enrollment
50 target
Eligibility
18 years · All sexes
Timeline
20212027

Study locations (1)

Collaborators

Pfizer

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04741997 on ClinicalTrials.gov

Other trials for Germ cell tumor

Additional recruiting or active studies for the same condition.

See all trials for Germ cell tumor

← Back to all trials